Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference
08 mars 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line...
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC
01 mars 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 01, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line...
Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
21 févr. 2023 16h05 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements
20 janv. 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Closes $8 Million Private Placement
09 janv. 2023 16h45 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Announces Pricing of $8 Million Private Placement
05 janv. 2023 08h10 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea
04 janv. 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update
20 déc. 2022 16h15 HE
|
Vivos Therapeutics, Inc
Second and Third Quarter 10-Q Filings Bring Vivos Currenton SEC Filings for Nasdaq Stock Market Purposes Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Dec. 20, 2022 ...
Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call
16 déc. 2022 07h30 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative...
Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems
15 déc. 2022 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus...